Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS.

N Engl J Med. 2019 Nov 21;381(21):2020-2031. doi: 10.1056/NEJMoa1910231. Epub 2019 Sep 28.

PMID:
31562796
2.

Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.

Dumble M, Crouthamel MC, Zhang SY, Schaber M, Levy D, Robell K, Liu Q, Figueroa DJ, Minthorn EA, Seefeld MA, Rouse MB, Rabindran SK, Heerding DA, Kumar R.

PLoS One. 2014 Jun 30;9(6):e100880. doi: 10.1371/journal.pone.0100880. eCollection 2014.

3.

Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.

Medina JR, Becker CJ, Blackledge CW, Duquenne C, Feng Y, Grant SW, Heerding D, Li WH, Miller WH, Romeril SP, Scherzer D, Shu A, Bobko MA, Chadderton AR, Dumble M, Gardiner CM, Gilbert S, Liu Q, Rabindran SK, Sudakin V, Xiang H, Brady PG, Campobasso N, Ward P, Axten JM.

J Med Chem. 2011 Mar 24;54(6):1871-95. doi: 10.1021/jm101527u. Epub 2011 Feb 22.

PMID:
21341675
4.

GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers.

Sabbatini P, Korenchuk S, Rowand JL, Groy A, Liu Q, Leperi D, Atkins C, Dumble M, Yang J, Anderson K, Kruger RG, Gontarek RR, Maksimchuk KR, Suravajjala S, Lapierre RR, Shotwell JB, Wilson JW, Chamberlain SD, Rabindran SK, Kumar R.

Mol Cancer Ther. 2009 Oct;8(10):2811-20. doi: 10.1158/1535-7163.MCT-09-0423.

5.

Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase.

Sabbatini P, Rowand JL, Groy A, Korenchuk S, Liu Q, Atkins C, Dumble M, Yang J, Anderson K, Wilson BJ, Emmitte KA, Rabindran SK, Kumar R.

Clin Cancer Res. 2009 May 1;15(9):3058-67. doi: 10.1158/1078-0432.CCR-08-2530. Epub 2009 Apr 21.

6.

Discovery of 4-(benzylaminomethylene)isoquinoline-1,3-(2H,4H)-diones and 4-[(pyridylmethyl)aminomethylene]isoquinoline-1,3-(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4.

Tsou HR, Liu X, Birnberg G, Kaplan J, Otteng M, Tran T, Kutterer K, Tang Z, Suayan R, Zask A, Ravi M, Bretz A, Grillo M, McGinnis JP, Rabindran SK, Ayral-Kaloustian S, Mansour TS.

J Med Chem. 2009 Apr 23;52(8):2289-310. doi: 10.1021/jm801026e.

PMID:
19317452
7.

Synthesis, SAR study and biological evaluation of novel pyrazolo[1,5-a]pyrimidin-7-yl phenyl amides as anti-proliferative agents.

Wang YD, Honores E, Wu B, Johnson S, Powell D, Miranda M, McGinnis JP, Discafani C, Rabindran SK, Cheng W, Krishnamurthy G.

Bioorg Med Chem. 2009 Mar 1;17(5):2091-100. doi: 10.1016/j.bmc.2008.12.046. Epub 2008 Dec 25.

PMID:
19200741
8.

4-(Phenylaminomethylene)isoquinoline-1,3(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4 (CDK4).

Tsou HR, Otteng M, Tran T, Floyd MB Jr, Reich M, Birnberg G, Kutterer K, Ayral-Kaloustian S, Ravi M, Nilakantan R, Grillo M, McGinnis JP, Rabindran SK.

J Med Chem. 2008 Jun 26;51(12):3507-25. doi: 10.1021/jm800072z.

PMID:
18494457
9.

Pyrazolo[1,5-a]pyrimidin-7-yl phenyl amides as novel antiproliferative agents: exploration of core and headpiece structure-activity relationships.

Powell D, Gopalsamy A, Wang YD, Zhang N, Miranda M, McGinnis JP, Rabindran SK.

Bioorg Med Chem Lett. 2007 Mar 15;17(6):1641-5. Epub 2007 Jan 13.

PMID:
17275298
10.

Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.

Ji H, Zhao X, Yuza Y, Shimamura T, Li D, Protopopov A, Jung BL, McNamara K, Xia H, Glatt KA, Thomas RK, Sasaki H, Horner JW, Eck M, Mitchell A, Sun Y, Al-Hashem R, Bronson RT, Rabindran SK, Discafani CM, Maher E, Shapiro GI, Meyerson M, Wong KK.

Proc Natl Acad Sci U S A. 2006 May 16;103(20):7817-22. Epub 2006 May 3.

11.

Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression.

Grillo M, Bott MJ, Khandke N, McGinnis JP, Miranda M, Meyyappan M, Rosfjord EC, Rabindran SK.

Breast Cancer Res Treat. 2006 Jan;95(2):185-94. Epub 2005 Dec 1.

PMID:
16319987
12.

Parallel synthesis and biological evaluation of 5,6,7,8-tetrahydrobenzothieno[2,3-d]pyrimidin-4(3H)-one cytotoxic agents selective for p21-deficient cells.

Jennings LD, Kincaid SL, Wang YD, Krishnamurthy G, Beyer CF, McGinnis JP, Miranda M, Discafani CM, Rabindran SK.

Bioorg Med Chem Lett. 2005 Nov 1;15(21):4731-5.

PMID:
16143523
13.

Antitumor activity of HER-2 inhibitors.

Rabindran SK.

Cancer Lett. 2005 Sep 8;227(1):9-23. Epub 2004 Dec 15. Review.

PMID:
16051028
14.

Inhibition of tumor cell proliferation by thieno[2,3-d]pyrimidin-4(1H)-one-based analogs.

Wang YD, Johnson S, Powell D, McGinnis JP, Miranda M, Rabindran SK.

Bioorg Med Chem Lett. 2005 Aug 15;15(16):3763-6.

PMID:
16005212
15.

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J, Haber DA.

Proc Natl Acad Sci U S A. 2005 May 24;102(21):7665-70. Epub 2005 May 16.

16.

Pyrazolo[1,5-a]pyrimidin-7-yl phenyl amides as novel anti-proliferative agents: parallel synthesis for lead optimization of amide region.

Gopalsamy A, Yang H, Ellingboe JW, Tsou HR, Zhang N, Honores E, Powell D, Miranda M, McGinnis JP, Rabindran SK.

Bioorg Med Chem Lett. 2005 Mar 15;15(6):1591-4.

PMID:
15745803
17.

Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.

Tsou HR, Overbeek-Klumpers EG, Hallett WA, Reich MF, Floyd MB, Johnson BD, Michalak RS, Nilakantan R, Discafani C, Golas J, Rabindran SK, Shen R, Shi X, Wang YF, Upeslacis J, Wissner A.

J Med Chem. 2005 Feb 24;48(4):1107-31.

PMID:
15715478
18.

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.

Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, Hallett WA, Johnson BD, Nilakantan R, Overbeek E, Reich MF, Shen R, Shi X, Tsou HR, Wang YF, Wissner A.

Cancer Res. 2004 Jun 1;64(11):3958-65.

19.

Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2).

Wissner A, Overbeek E, Reich MF, Floyd MB, Johnson BD, Mamuya N, Rosfjord EC, Discafani C, Davis R, Shi X, Rabindran SK, Gruber BC, Ye F, Hallett WA, Nilakantan R, Shen R, Wang YF, Greenberger LM, Tsou HR.

J Med Chem. 2003 Jan 2;46(1):49-63.

PMID:
12502359
20.

Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents.

Wissner A, Brawner Floyd MB, Rabindran SK, Nilakantan R, Greenberger LM, Shen R, Wang YF, Tsou HR.

Bioorg Med Chem Lett. 2002 Oct 21;12(20):2893-7.

PMID:
12270171
21.

4-Anilino-3-cyanobenzo[g]quinolines as kinase inhibitors.

Zhang N, Wu B, Wissner A, Powell DW, Rabindran SK, Kohler C, Boschelli F.

Bioorg Med Chem Lett. 2002 Feb 11;12(3):423-5.

PMID:
11814812
22.

A novel association between the human heat shock transcription factor 1 (HSF1) and prostate adenocarcinoma.

Hoang AT, Huang J, Rudra-Ganguly N, Zheng J, Powell WC, Rabindran SK, Wu C, Roy-Burman P.

Am J Pathol. 2000 Mar;156(3):857-64.

23.

Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein.

Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM.

Cancer Res. 2000 Jan 1;60(1):47-50.

24.

Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C.

Rabindran SK, He H, Singh M, Brown E, Collins KI, Annable T, Greenberger LM.

Cancer Res. 1998 Dec 15;58(24):5850-8.

25.

Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.

Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, Baylin SB, Kern SE, Herman JG.

Cancer Res. 1997 Aug 1;57(15):3126-30.

26.

Displacement of sequence-specific transcription factors from mitotic chromatin.

Martínez-Balbás MA, Dey A, Rabindran SK, Ozato K, Wu C.

Cell. 1995 Oct 6;83(1):29-38.

27.

Stimulation of the DNA-dependent protein kinase by RNA polymerase II transcriptional activator proteins.

Peterson SR, Jesch SA, Chamberlin TN, Dvir A, Rabindran SK, Wu C, Dynan WS.

J Biol Chem. 1995 Jan 20;270(3):1449-54.

28.

Interaction between heat shock factor and hsp70 is insufficient to suppress induction of DNA-binding activity in vivo.

Rabindran SK, Wisniewski J, Li L, Li GC, Wu C.

Mol Cell Biol. 1994 Oct;14(10):6552-60.

29.

Regulation of heat shock factor trimer formation: role of a conserved leucine zipper.

Rabindran SK, Haroun RI, Clos J, Wisniewski J, Wu C.

Science. 1993 Jan 8;259(5092):230-4.

PMID:
8421783
30.

Molecular cloning and expression of a human heat shock factor, HSF1.

Rabindran SK, Giorgi G, Clos J, Wu C.

Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):6906-10.

31.

Two point mutations in the hormone-binding domain of the mouse glucocorticoid receptor that dramatically reduce its function.

Byravan S, Milhon J, Rabindran SK, Olinger B, Garabedian MJ, Danielsen M, Stallcup MR.

Mol Endocrinol. 1991 Jun;5(6):752-8.

PMID:
1922094
32.

Heat shock-regulated transcription in vitro from a reconstituted chromatin template.

Becker PB, Rabindran SK, Wu C.

Proc Natl Acad Sci U S A. 1991 May 15;88(10):4109-13.

34.

Glucocorticoid-resistant lymphoma cell variants that contain functional glucocorticoid receptors.

Rabindran SK, Danielsen M, Stallcup MR.

Mol Cell Biol. 1987 Dec;7(12):4211-7.

35.
36.

Glucocorticoid-dependent maturation of viral proteins in mouse lymphoma cells: isolation of defective and hormone-independent cell variants.

Rabindran SK, Danielsen M, Firestone GL, Stallcup MR.

Somat Cell Mol Genet. 1987 Mar;13(2):131-43.

PMID:
3031826

Supplemental Content

Loading ...
Support Center